HK Stock Market Move | LIVZON PHARMA (01513) rose more than 5% in late trading; third-quarter results improved quarter-on-quarter; the company has formulated a shareholder return plan for the next three years.

LIVZON PHARMA (01513) rose more than 5% in late trading. As of press time, it was up 4.95% at HK$23.32, with a turnover of HK$35.1731 million. On the news front, LIVZON PHARMA released its results, with revenue of RMB7.319 billion for the first three quarters, down 19.71% year-on-year; net profit attributable to shareholders of RMB1.288 billion, down 26.57% year-on-year. CICC said the company's first three quarters results were in line with market expectations, with revenue and net profit improving quarter-on-quarter in the third quarter alone. In the third quarter alone, the company's revenue rose 8.97% quarter-on-quarter, net profit attributable to shareholders rose 0.17% quarter-on-quarter, and net profit attributable to shareholders after deducting non-recurring gains and losses rose 18.82% quarter-on-quarter. It is worth noting that LIVZON PHARMA plans to distribute a cash dividend of RMB12.39 per 10 shares (tax inclusive) to all shareholders, with total cash dividends expected to be RMB1.10 billion. The company has also formulated a shareholder return plan for the next three years, specifying that, subject to conditions for cash dividends being met, the total annual cash dividend amount in principle shall be no less than 90% of the distributable profit realized in the current year, and the total annual cash dividend amount in principle shall be no less than RMB2 billion (tax inclusive).